Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endo International PLC (NASDAQ:ENDP)

15.64
Delayed Data
As of Dec 09
 -0.01 / -0.06%
Today’s Change
12.56
Today|||52-Week Range
63.63
-74.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$3.5B

Company Description

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded on October 31, 2013 and is headquartered Dublin, Ireland.

Contact Information

Endo International Plc
First Floor, Minerva House
Dublin Dublin 4
P:(531) 268-2000
Investor Relations:
3534842167912

Employees

Shareholders

Mutual fund holders48.82%
Other institutional36.27%
Individual stakeholders0.73%

Top Executives

Paul V. CampanelliPresident, Chief Executive Officer & Director
Terrance J. CoughlinChief Operating Officer & Executive Vice President
Blaise ColemanChief Financial Officer
Robert J. CobuzziSVP-Operations, Research & Development Strategy
Joseph A. BarbariteEVP-Global Quality & Compliance